NUR 7600 Module 3 Antipsychotic Case: First-Episode Psychosis and Metabolic Risk Example

Similar Relief, Different Costs: Choosing a First Antipsychotic for a 22-Year-Old by Weighing Efficacy, Discontinuation and Metabolic Harm

Student Name

M.S. in Nursing, Psychiatric Mental Health Nurse Practitioner, Thomas Edison State University

NUR-7600: Psychopharmacology and Neuroscience Foundations Across the Lifespan

Mentor Name

Month Day, Year

Similar Relief, Different Costs: Choosing a First Antipsychotic for a 22-Year-Old by Weighing Efficacy, Discontinuation and Metabolic Harm

Introduction

Mr. D. is an invented patient, a 22-year-old community college student in Newark who lives with his mother and younger sisters. Over four months he began hearing two voices commenting on his actions and became convinced that classmates were recording him. He stopped attending classes, stays in his room and sleeps irregularly. He does not use cannabis or other drugs, a urine screen is negative, and a medical evaluation, including thyroid tests and a neurological examination, is normal. He has no history of mania. He is not violent and denies thoughts of harming himself or others. His mother brought him to an early psychosis clinic. He agrees to take medicine if it will "make the voices quieter" but is worried about gaining weight, as his cousin did on medication. This paper chooses his first antipsychotic.

How Antipsychotics Work

Positive symptoms of psychosis, such as hallucinations and delusions, are associated with excess dopamine signaling in the mesolimbic pathway. All current antipsychotics block or modulate the dopamine D2 receptor. Full antagonists such as haloperidol block the receptor, which reduces psychosis but also blocks dopamine in the nigrostriatal pathway, causing movement side effects, and in the tuberoinfundibular pathway, raising prolactin. Second-generation drugs add serotonin 5-HT2A antagonism, which may reduce movement effects. Aripiprazole is a D2 partial agonist: it occupies the receptor and produces a lower level of activity than dopamine, lowering signaling where dopamine is excessive while partly preserving it where dopamine is low. This mechanism explains its low rates of movement effects and prolactin elevation.

The same partial agonism explains its main drawback. Because aripiprazole provides some stimulation at the receptor, it can produce akathisia, an inner restlessness that patients describe as being unable to sit still, particularly early in treatment and at higher starting doses. Akathisia is distressing, can be mistaken for worsening psychosis or anxiety and is a common reason young patients stop taking the drug, so it shapes the dosing plan below.

Efficacy: Small Differences

Huhn et al. (2019) pooled 402 schizophrenia trials, over fifty thousand people, in one network. All 32 antipsychotics reduced overall symptoms more than placebo, although six did not reach statistical significance. Clozapine had the largest effect, but it is reserved for treatment-resistant illness because of its risks. Among the others, differences in efficacy were modest, while differences in side effects were large: rates of sedation, the need for antiparkinson drugs, weight gain and prolactin elevation varied widely.

The European First Episode Schizophrenia Trial reached a similar conclusion in first-episode patients. Kahn et al. (2008) randomized patients to haloperidol or one of four second-generation drugs and followed them for a year. Symptom reductions were about 60 percent in all groups, but discontinuation for any cause differed greatly, from 72 percent with haloperidol to 33 percent with olanzapine and 40 to 53 percent with the others. Staying on treatment, not the strength of the drug, distinguished the options.

Metabolic Harm: Large Differences

Pillinger et al. (2020) ranked 18 antipsychotics by their effects on weight, body mass index, cholesterol, triglycerides and glucose across 100 trials. Olanzapine and clozapine caused the most metabolic disturbance, while drugs such as aripiprazole, brexpiprazole, cariprazine and lurasidone caused less. Higher baseline weight and male sex predicted larger rises in glucose. Young people in their first episode are particularly sensitive to weight gain, and metabolic disease is a major reason for the shortened life expectancy of people with schizophrenia.

Mr. D. is male and already slightly above a healthy weight, with a body mass index of 26, so both predictors apply to him. The authors also found that improvement in symptoms was associated with weight gain, a reminder that the trade-off between benefit and harm is real and must be discussed openly rather than hidden from the patient.

The Choice and the Order

Given similar efficacy, his concern about weight and the evidence on metabolic harm, aripiprazole is chosen. The order is aripiprazole 5 milligrams by mouth once daily, increased to 10 milligrams after one to two weeks if tolerated, with a usual range of 10 to 15 milligrams for first-episode patients. Lower doses are often effective in a first episode, and starting low reduces akathisia, a restless urge to move that is aripiprazole's most common troublesome effect. If akathisia appears, the dose is reduced or a low dose of propranolol is added.

Monitoring

On day one the nurse measures his weight, BMI, waist and blood pressure, and blood is drawn for an A1c or fasting sugar and a cholesterol panel. Weight is checked at every visit for the first three months, and glucose and lipids are repeated at 12 weeks and then yearly. An increase of 5 percent or more in body weight prompts a review of diet, activity and, if needed, a change of drug. Movement effects are assessed with a rating scale at baseline and periodically. Response is measured with a symptom scale at each visit, with an adequate trial defined as several weeks at a therapeutic dose.

Engagement and Family

Discontinuation is the main threat to his recovery, as the first-episode trial showed. Mr. D. will be seen every two weeks at first by the same clinician, his goals, returning to classes and fewer arguments at home, will be written into the plan, and a family session will explain psychosis and the medication to his mother. Coordinated specialty care, which includes psychotherapy, family education and supported education, is offered alongside medication.

Conclusion

Antipsychotics differ less in how well they relieve psychosis than in how often patients stop them and what they do to the body. For a 22-year-old worried about weight, aripiprazole offers effective treatment with lower metabolic risk, through a partial agonist mechanism that also limits movement and prolactin effects. A low starting dose, metabolic monitoring and close engagement with him and his family are what will keep him on treatment.

References

Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, 394(10202), 939-951. https://doi.org/10.1016/S0140-6736(19)31135-3

Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P. M., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J. J., Hranov, L. G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., Grobbee, D. E., & EUFEST study group. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. The Lancet, 371(9618), 1085-1097. https://doi.org/10.1016/S0140-6736(08)60486-9

Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry, 7(1), 64-77. https://doi.org/10.1016/S2215-0366(19)30416-X